News and Announcements
Emergence 2022: Capital Raising Insights From Jason Calacanis
- Published December 20, 2022 12:37AM UTC
- Publisher Leila Oliveira
- Categories Capital Raising Tips
3 insights from Jason Calacanis at Emergence 2022:
๐๐๐ฅ๐ฎ๐๐ญ๐ข๐จ๐ง
15 years a series A round would be around 3-5M dollars. Now we see seed rounds raising this amount with no governance, no lead investor and thatโs a recipe for disaster as the company will suffer when the market corrects. He calls it the valuation trap.
“Iโm not saying to ask for a lower valuation, but founders, investors and board members should be aware of the risks of a wrong valuation. Those crazy high valuations weโve seen during COVID, theyโre gone. such as Snowflake, Peloton, Doordash.”
๐๐ก๐๐ญ ๐ฌ๐๐๐ญ๐จ๐ซ ๐๐ฑ๐๐ข๐ญ๐๐ฌ ๐ฒ๐จ๐ฎ ๐ญ๐ก๐ ๐ฆ๐จ๐ฌ๐ญ?
His excitement is not dependent on the sector but on the founder; However, he mentions:
โช๏ธ FinTech
โช๏ธ Marketplace
โช๏ธ SaaS
โช๏ธ Consumer software and consumer subscriptions
๐๐ก๐๐ญ ๐๐ซ๐ ๐ญ๐ก๐ ๐ฆ๐จ๐ฌ๐ญ ๐ข๐ฆ๐ฉ๐จ๐ซ๐ญ๐๐ง๐ญ ๐ช๐ฎ๐๐ฅ๐ข๐ญ๐ข๐๐ฌ ๐ฒ๐จ๐ฎ ๐ฅ๐จ๐จ๐ค ๐๐จ๐ซ ๐ข๐ง ๐ ๐๐จ๐ฎ๐ง๐๐๐ซ?
High energy, resilience and grit.
Grit alone isnโt enough. You need to be able to recruit and build a great product.
๐ He also shared his thoughts on the blockchain, web3 and strategic investors.
Would you like part 2 with these topics?
Click here to view the original Linkedin post.
Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.
Your capital engagement platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Capital Raising Tips
The Systemโs Immune System: Why Big Tech Will Solve What Big Pharma Canโt
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science expertsโtreating biology as a data and compute problemโrepresents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decksโit’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7โ$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
